ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
Tunnah
|
1.3K |
543K |
9 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
1.3K
|
543K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
|
|
Tunnah
|
914 |
286K |
5 |
01/02/23 |
01/02/23 |
ASX - By Stock
|
914
|
286K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
|
|
Tunnah
|
408 |
122K |
3 |
16/12/21 |
16/12/21 |
ASX - By Stock
|
408
|
122K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Give Tommy a Headline!
|
|
Tunnah
|
77 |
17K |
1 |
01/09/21 |
01/09/21 |
ASX - By Stock
|
77
|
17K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Give Tommy a Headline!
|
|
Tunnah
|
77 |
17K |
4 |
01/09/21 |
01/09/21 |
ASX - By Stock
|
77
|
17K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Give Tommy a Headline!
|
|
Tunnah
|
77 |
17K |
5 |
31/08/21 |
31/08/21 |
ASX - By Stock
|
77
|
17K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Tunnah
|
17K |
6.6M |
23 |
31/03/21 |
31/03/21 |
ASX - By Stock
|
17K
|
6.6M
|
23
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast readies $100m private placement
|
|
Tunnah
|
396 |
118K |
7 |
28/02/21 |
28/02/21 |
ASX - By Stock
|
396
|
118K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
|
|
Tunnah
|
763 |
323K |
7 |
11/01/21 |
11/01/21 |
ASX - By Stock
|
763
|
323K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Tunnah
|
13K |
4.9M |
7 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
7
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Tunnah
|
13K |
4.9M |
4 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Tunnah
|
13K |
4.9M |
6 |
17/12/20 |
17/12/20 |
ASX - By Stock
|
13K
|
4.9M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Tunnah
|
796 |
393K |
6 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
393K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Tunnah
|
796 |
393K |
2 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
393K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Tunnah
|
796 |
393K |
22 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
393K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Tunnah
|
796 |
393K |
5 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
393K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Tunnah
|
796 |
393K |
3 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
393K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Tunnah
|
796 |
393K |
12 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
393K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
Tunnah
|
1.0K |
416K |
17 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
416K
|
17
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Trading Halt
|
|
Tunnah
|
192 |
35K |
0 |
09/12/20 |
09/12/20 |
ASX - By Stock
|
192
|
35K
|
0
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Trading Halt
|
|
Tunnah
|
192 |
35K |
12 |
09/12/20 |
09/12/20 |
ASX - By Stock
|
192
|
35K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
Tunnah
|
572 |
250K |
18 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
572
|
250K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Tunnah
|
13K |
4.9M |
2 |
23/11/20 |
23/11/20 |
ASX - By Stock
|
13K
|
4.9M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
Tunnah
|
445 |
193K |
1 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
445
|
193K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
|
|
Tunnah
|
392 |
157K |
0 |
12/11/20 |
12/11/20 |
ASX - By Stock
|
392
|
157K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
|
|
Tunnah
|
392 |
157K |
22 |
11/11/20 |
11/11/20 |
ASX - By Stock
|
392
|
157K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
|
|
Tunnah
|
392 |
157K |
21 |
11/11/20 |
11/11/20 |
ASX - By Stock
|
392
|
157K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
|
|
Tunnah
|
392 |
157K |
5 |
11/11/20 |
11/11/20 |
ASX - By Stock
|
392
|
157K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
|
|
Tunnah
|
392 |
157K |
48 |
11/11/20 |
11/11/20 |
ASX - By Stock
|
392
|
157K
|
48
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Kayelekera Mine Restart Study
|
|
Tunnah
|
13 |
3.0K |
1 |
20/10/20 |
20/10/20 |
ASX - By Stock
|
13
|
3.0K
|
1
|
|
ASX - By Stock
|
LOT |
Re:
Ann: Kayelekera Mine Restart Study
|
|
Tunnah
|
13 |
3.0K |
2 |
20/10/20 |
20/10/20 |
ASX - By Stock
|
13
|
3.0K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
Tunnah
|
445 |
193K |
0 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
445
|
193K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
Tunnah
|
445 |
193K |
13 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
445
|
193K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
Tunnah
|
445 |
193K |
12 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
445
|
193K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
Tunnah
|
445 |
193K |
6 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
445
|
193K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
Tunnah
|
445 |
193K |
5 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
445
|
193K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
Tunnah
|
445 |
193K |
2 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
445
|
193K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
Tunnah
|
445 |
193K |
2 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
445
|
193K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
Tunnah
|
445 |
193K |
3 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
445
|
193K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
Tunnah
|
445 |
193K |
6 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
445
|
193K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
Tunnah
|
445 |
193K |
4 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
445
|
193K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
Tunnah
|
445 |
193K |
11 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
445
|
193K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
Tunnah
|
445 |
193K |
11 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
445
|
193K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment
|
|
Tunnah
|
445 |
193K |
24 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
445
|
193K
|
24
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Tunnah
|
13K |
4.9M |
5 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
13K
|
4.9M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Tunnah
|
13K |
4.9M |
1 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
13K
|
4.9M
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Tunnah
|
13K |
4.9M |
6 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
13K
|
4.9M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Tunnah
|
13K |
4.9M |
3 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
13K
|
4.9M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Tunnah
|
13K |
4.9M |
18 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
13K
|
4.9M
|
18
|
|
ASX - By Stock
|
CYP |
Re:
CYP vs MSB
|
|
Tunnah
|
644 |
123K |
1 |
13/10/20 |
13/10/20 |
ASX - By Stock
|
644
|
123K
|
1
|
|